The future of epigenetic therapy in solid tumours - Lessons from the past

Research output: Contribution to journalReview article

Abstract

The promise of targeting epigenetic abnormalities for cancer therapy has not been realized for solid tumours, although increasing evidence is demonstrating its worth in haematological malignancies. In fact, true clinical efficacy in haematopoietic-related neoplasms has only become evident at low doses of epigenetic-targeting drugs (namely, inhibitors of histone deacetylase and DNA methyltransferases). Describing data from preclinical studies and early clinical trial results, we hypothesize that in using low-dose epigenetic-modulating agents, tumour cells can be reprogrammed, which overrides any immediate cytotoxic and off-target effect observed at high dose. We suggest that such optimization of drug dosing and scheduling of currently available agents could give these agents a prominent place in cancer management - when used alone or in combination with other therapies. If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome.

Original languageEnglish (US)
Pages (from-to)256-266
Number of pages11
JournalNature Reviews Clinical Oncology
Volume10
Issue number5
DOIs
StatePublished - May 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this